We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

103 hedge funds and large institutions have $140M invested in Sanofi Contingent Value Rights in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $87.5M → $140M (+$52.1M)

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

0% more funds holding

Funds holding: 103 → 103 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
103
Holders Change
–
Holders Change %
0%
% of All Funds
2.03%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
14
Increased
11
Reduced
15
Closed
13
Calls
$17.9M
Puts
–
Net Calls
+$17.9M
Net Calls Change
+$913K

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$1.82M
2
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$1.18M
3
OP
Omni Partners
United Kingdom
+$1.11M
4
JCI
Jet Capital Investors
New York
+$729K
5
SCM
Stonehill Capital Management
New York
+$553K

Top Sellers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
-$280K
2
NGA
New Generation Advisors
Massachusetts
-$151K
3
BRF
B. Riley Financial
California
-$144K
4
TL
TowerView LLC
New York
-$127K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$100K
Name Holding Trade Value Shares
Change 		Change in
Stake
JC
26
JBF Capital
Colorado
$114K +$102K +132,702 New
UBS Group
27
UBS Group
Switzerland
$78K +$30.3K +39,500 +77%
GI
28
GAMCO Investors
Connecticut
$54K – – –
Royal London Asset Management
29
Royal London Asset Management
United Kingdom
$36K -$2.21K -2,885 -7%
ZIG
30
Zuckerman Investment Group
Illinois
$36K -$203 -265 -0.6%
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$35K +$18.9K +24,580 +147%
Citadel Advisors
32
Citadel Advisors
Florida
$26K +$23.6K +30,684 New
Bank of America
33
Bank of America
North Carolina
$23K -$89 -116 -0.4%
Ameriprise
34
Ameriprise
Minnesota
$16K -$322 -420 -2%
HKAM
35
Horizon Kinetics Asset Management
New York
$14K – – –
LPL Financial
36
LPL Financial
California
$14K – – –
MC
37
Moors & Cabot
Massachusetts
$14K – – –
CHAM
38
Clear Harbor Asset Management
Connecticut
$13.4K – – –
RWP
39
RWA Wealth Partners
Massachusetts
$13K – – –
William Blair & Company
40
William Blair & Company
Illinois
$12K – – –
EAM
41
Erste Asset Management
Austria
$10.3K – – –
BlackRock
42
BlackRock
New York
$10K – – –
BIA
43
Biondo Investment Advisors
Pennsylvania
$9K – – –
DA
44
Dillon & Associates
Michigan
$9K – – –
Morgan Stanley
45
Morgan Stanley
New York
$8K -$14.7K -19,117 -67%
Wells Fargo
46
Wells Fargo
California
$7K -$76.9K -100,143 -93%
Deutsche Bank
47
Deutsche Bank
Germany
$6K – – –
PNC Financial Services Group
48
PNC Financial Services Group
Pennsylvania
$6K – – –
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$5K – – –
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$4.69K – – –
1
2
3 4

GCVRZ Hedge Fund Activity: Q4 2019 in Review

103 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2019, worth a combined $140M — up 60% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GCVRZ positions and 13 closed out — a net gain of 1 holder — while 11 added to existing stakes and 15 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $1.82M. The largest seller was Wexford Capital, exiting entirely with an estimated $280K sold.

  • 103 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $140M of Sanofi Contingent Value Rights stock for Q4 2019, up 60% quarter-over-quarter.
  • 14 funds opened new Sanofi Contingent Value Rights positions in Q4 2019 and 13 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2019 was Farallon Capital Management, an estimated $1.82M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2019 was Wexford Capital, an estimated $280K sold.

Based on aggregated 13F filings for Q4 2019.